The digital intervention of a glycated albumin (GA) self-monitoring system for patients with type 2 diabetes: a randomized, open-label, non-intervention group controlled, single-center clinical study

Jinnouchi Hideaki0 个研究点目标入组 100 人开始时间: 2022年8月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients who meet the diagnostic criteria for type 2 diabetes mellitus of the Japan Diabetes Society
•(2) Patients whose HbA1c measured on the date of consent is 7.0 or higher and 9.0 or lower
•(3) Patients who understand the contents of the consent document describing the purpose and methods of the study and agree in writing to participate in the study.
•(4) Patients who are 20 years of age or older at the time consent is obtained
•(5) Patients who have a smartphone that can use the application

•(1) Patients on insulin therapy
•(2) Patients on GLP-1 injection therapy
•(3) Patients under inpatient care
•(4) Patients with confirmed or suspected type 1 diabetes
•(5) Patients whose HbA1c level has changed 0.8% or more in the 2 visits prior to obtaining consent and whose symptoms have not stabilized
•(6) Patients who have undergone a change in drug therapy in the 2 months prior to obtaining consent and whose therapeutic response has not stabilized
•(7) Patients who have difficulty or prohibit from following diet or exercise therapy due to other medical conditions
•(8) Severely obese patients (BMI > 35)
•(9) Patients with diseases or conditions known to cause a discrepancy between GA and blood glucose levels (hyperthyroidism, nephrosis, ascites (peritoneal dialysis), steroid diabetes, high BMI, hypothyroidism, liver cirrhosis, hyponutrition)
•(10) Patients with concomitant diseases that affect HbA1c test values (abnormal hemoglobinemia, hemolytic anemia, bleeding disorders, renal failure, patients receiving erythropoietin)
•(11) Patients with inadequate responses to required questionnaires
•(12) Patients with difficulty in self finger-prick blood sampling

发起方

Jinnouchi Hideaki